CA9hu-1
/ Mabpro
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
March 15, 2023
CAMP1: Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours
(clinicaltrials.gov)
- P1 | N=50 | Not yet recruiting | Sponsor: Mabpro, a.s. | Trial completion date: Jan 2026 ➔ Jan 2027 | Initiation date: Jan 2023 ➔ Jan 2024 | Trial primary completion date: Jan 2025 ➔ Jan 2026
Metastases • Trial completion date • Trial initiation date • Trial primary completion date • Breast Cancer • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer • CA9
January 26, 2023
CAMP1: Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours
(clinicaltrials.gov)
- P1 | N=50 | Not yet recruiting | Sponsor: Mabpro, a.s.
Metastases • New P1 trial • Breast Cancer • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer • CA9
1 to 2
Of
2
Go to page
1